ABSTRACT
We describe the identification of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine (3), a potent, orally active Src inhibitor with desirable PK properties, demonstrated activity in human tumor cell lines and in animal models of tumor growth.
Subject(s)
Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacology , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Pyrrolidines/chemical synthesis , Triazines/chemical synthesis , src-Family Kinases/antagonists & inhibitors , Animals , Antineoplastic Agents/pharmacokinetics , Cell Line, Tumor , Cytochrome P-450 Enzyme Inhibitors , Dogs , Enzyme Inhibitors/pharmacokinetics , Half-Life , Humans , Isoenzymes/antagonists & inhibitors , Lung Neoplasms/drug therapy , Mice , Mice, Nude , Models, Molecular , Molecular Conformation , Neoplasm Transplantation , Protein Binding , Pyrrolidines/pharmacology , Rats , Structure-Activity Relationship , Triazines/pharmacologyABSTRACT
A direct comparison of the inhibitory effects of alpha, beta, and gamma interferons (IFNs) on replication of a hepatitis C virus subgenomic replicon in a hepatoma cell line revealed similarities in antiviral potency. However, alternate IFN-induced antiviral mechanisms were suggested following observations of striking differences between IFN-gamma and IFN-alpha/beta with respect to strength and durability of the antiviral response and the magnitude and pattern of IFN-mediated gene expression.
